18:52 , Oct 5, 2017 |  BC Innovations  |  Translation in Brief

SSRIs' first responders

Researchers at The Rockefeller University have identified a role for CCK-expressing neurons in initiating responses to SSRIs for depression and manipulated the neurons to recapitulate the drugs' effects. The findings could lead to faster-acting antidepressants...
21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...
21:05 , Jul 18, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of S100A10 , S100A11 and TNC mRNAs could help predict survival in lung cancer. In 57 lung adenocarcinoma patients, mRNA levels of S100A10, S100A11 and TNC were higher in tumors...
23:48 , Feb 28, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Leukocyte levels of S100A10 in could help diagnose PD. In peripheral cytotoxic T cells from patients, S100A10 levels were lower than in cytotoxic T cells from healthy volunteers, and S100A10 levels in...
08:00 , Mar 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Annexin A2 (ANXA2); helicase-like transcription factor (HLTF; SMARCA3); S100 calcium binding protein A10 (S100A10; P11) Mouse and in vitro studies...
08:00 , Nov 11, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression S100 calcium binding protein A10 (S100A10; P11) Mouse studies suggest that restoring P11 expression in the brain could help treat depression. Compared with using...
07:00 , Nov 4, 2010 |  BC Innovations  |  Targets & Mechanisms

Depression paths of least resistance

A pair of reports from U.S. and European researchers point to new targets in depression that could offer treatment alternatives to patients who are resistant or unresponsive to marketed antidepressants. 1,2 One of the new...
08:00 , Feb 21, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Serotonin receptor (5-HT1B receptor) A study in rodents suggests that 5-HT1B receptor agonists might be useful for reducing l-DOPA side effects in...